# A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

> **NCT06779851** · PHASE1 · TERMINATED · sponsor: **Bright Peak Therapeutics Inc** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BPT567

## Key facts

- **NCT ID:** NCT06779851
- **Lead sponsor:** Bright Peak Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-15
- **Primary completion:** 2026-01-21
- **Final completion:** 2026-03-11
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06779851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06779851, "A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06779851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*